Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers are critical to the future of biotech.
Generate’s Chief IP ‘Geek’ Wants To Answer AI’s Biggest Legal Questions Read More »
If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 agreements signed in 2024.
Pharma Spent More Than $48B in China in H1, Eclipsing Total 2024 Haul Read More »
As new CEO Ashley McEvoy lays the groundwork to build the brand globally, the diabetes tech company also hired Manoj Raghunandanan as chief growth officer.
Insulet promotes Eric Benjamin to chief operating officer Read More »
The Baltimore-based system and the major insurer failed to resolve their contract spat by Monday’s deadline, sending some 60,000 patients out of network. Both pledged to continue negotiations.
CEO Eric Lefkofsky said that buying Paige “substantially accelerates” Tempus’ effort to build the largest foundation model in oncology.
Tempus inks $81M Paige buyout to support AI model development Read More »
La localización, en torno al planeta Urano, de un satélite que hasta ahora había pasado desapercibido, eleva a un total de 29 las lunas en órbita a dicho mundo. El hallazgo lo ha hecho un equipo encabezado por Maryame El Moutamid, del Instituto de Investigaci&oac …
Unos investigadores han conseguido grabar imágenes inéditas del proceso de implantación de un embrión humano. Se trata de la primera vez que se consigue grabar la implantación en tiempo real y en 3D. El logro es obra de científicos del Instituto de …
Graban por vez primera el proceso de implantación de un embrión humano Read More »
Hace 10.000 años, los mastodontes desaparecieron de América del Sur. Con ellos se extinguió también una función ecológica que hoy resulta vital: la dispersión de semillas de plantas con frutos grandes. Un nuevo estudio demuestra por primera vez, a par …
La desaparición de los mastodontes aún pone en riesgo la flora nativa de América del Sur Read More »
While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition,” they also pointed to a manufacturing advantage that could unlock a “double-digit billion dollar opportunity” for Eli Lilly.
Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron Read More »
The medical transportation firm blamed mounting headwinds for its financial challenges, including labor cost inflation and declining reimbursements from public payers.
ModivCare files for bankruptcy with over $1.4B in debt Read More »
